Antiglaucomatous effects of the activation of intrinsic angiotensin-converting enzyme 2

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 6, 2013, Pages 4296-4306

  Foureaux, Giselle ^a   Nogueira, José C ^a   Nogueira, Bárbara S ^a   Fulgêncio, Gustavo O ^a   Menezes, Gustavo B ^a   Fernandes, Simone O A ^a   Cardoso, Valbert N ^a   Fernandes, Renata S ^a   Oliveira, Gabriel P ^a   Franca, Juçara R ^a   Faraco, André A G ^a   Raizada, Mohan K ^b   Ferreira, Anderson J ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

ACE2 activation; Angiotensin (1 7); Eyes; Glaucoma; Mas receptor; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CASPASE 3; DIMINAZENE ACETURATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR FLOW; ARTICLE; CELL COUNT; CONTROLLED STUDY; GLAUCOMA; HISTOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MEAN ARTERIAL PRESSURE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA GANGLION CELL; SCINTIGRAPHY; TONOMETRY; TRANSMISSION ELECTRON MICROSCOPY;

ACE2 ACTIVATION; ANGIOTENSIN-(1-7); EYES; GLAUCOMA; MAS RECEPTOR; RENIN-ANGIOTENSIN SYSTEM;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BLOOD PRESSURE; CASPASE 3; CELL COUNT; DIMINAZENE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLAUCOMA; IMMUNOENZYME TECHNIQUES; INTRAOCULAR PRESSURE; MALE; NERVE FIBERS; OPHTHALMIC SOLUTIONS; OPTIC NERVE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; RETINA; RETINAL GANGLION CELLS; SULFONAMIDES; THIOPHENES; TONOMETRY, OCULAR;

EID: 84879156053     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11427     Document Type: Article

References (35)

1. Pang IH, Clark AF. Rodent models for glaucoma retinopathy and optic neuropathy. J Glaucoma. 2007;16:483-505.
2. Johnson TV, Tomarev SI. Rodent models of glaucoma. Brain Res Bull. 2010;81:349-358.
3. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000; 107:1287-1293.
4. Luo BP, Brown GC. Update on the ocular manifestations of systemic arterial hypertension. Curr Opin Ophthalmol. 2004; 15:203-210.
5. Vaajanen A, Lakkisto P, Virtanen I, et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol. 2009;88:431-438.
6. Ferreira AJ, Bader M, Santos RAS. Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the reninangiotensin system: a patent review. Expert Opin Ther Pat. 2012;22:567-574.
7. Santos RA, Ferreira AJ, Nadu AP, et al. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics. 2004;17:292-299.
8. Santos RA, Ferreira AJ, Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93:519-527.
9. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515-521.
10. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res. 2005;38:499-507.
11. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
12. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
13. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
14. Rojanapongpun P, Drance SM, Morrison BJ. Ophthalmic artery flow velocity in glaucomatous and normal subjects. Br J Ophthalmol. 1993;77:25-29.
15. Danser AHJ, Derkx FHM, Admiraal PJJ, Deinum J, De Jong PTVM, Schalekamp MADH. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994;35:1008-1018.
16. Wagner J, Danser AHJ, Derkx FHM, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996;80:159-163.
17. Savaskan E, Loffler KU, Meier F, Muller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensinconverting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res. 2004;36:312-320.
18. Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther. 2009;25:23-28.
19. Senanayake Pd, Drazba J, Shadrach K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007;48:3301-3311.
20. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011;16: 878-885.
21. Moreno MC, Aldana Marcos HJ, Croxatto JO, et al. A new experimental model of glaucoma in rats through intracameral injections of hyaluronic acid. Exp Eye Res. 2005;81:71-80.
22. Diniz SOF, Rezende CMF, Serakides R, et al. Scintigraphic imaging using technetium-99m-labeled ceftizoxime in an experimental model of acute osteomyelitis in rats. Nucl Med Commun. 2008;29:830-836.
23. Tikellis C, Johnston CI, Forbes JM, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res. 2004;29:419-427.
24. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011;96:287-294.
25. Murça TM, Moraes PL, Capuruco CAB, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept. 2012; 177:107-115.
26. Vaajanen A, Vapaatalo H, Kautiainen H, Oksala O. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci. 2008;49:2557-2562.
27. Okisaka S, Murakami A, Mizukawa A, Junji I. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol. 1997;41:84-88.
28. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv Ophthalmol. 1999;43:S151-S161.
29. Hashizume K, Mashima Y, Fumayama T, et al. Genetic polymorphisms in the angiotensin II receptor gene and their association with open-angle glaucoma in a Japanese population. Invest Ophthalmol Vis Sci. 2005;46:1993-2001.
30. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci. 1995;36:1765-1773.
31. Santos RAS, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000;91:45-62.
32. Kostenis E, Milligan G, Christopoulos A, et al. G-proteincoupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation. 2005;111:1806-1813.
33. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol. 1999;43: S129-S135.
34. Vorwerk CK, Hyman BT, Miller JW, et al. The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity. Invest Ophthalmol Vis Sci. 1997;38:2038-2044.
35. Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000;36:169-175.